Table 1 Baseline characteristics of patient cohort.
DDIR negative (n = 88) | DDIR positive (n = 25) | p-value | |
|---|---|---|---|
Age (years) median (range, IQR) | 63.00 (28.00–83.00, 9.25) | 62.00 (47.00–78.00, 11.00) | 0.88 |
Gender | |||
Male | 66 (75.00%) | 22 (88.00%) | 0.27 |
Female | 22 (25.00%) | 3 (12.00%) | |
Chemotherapy regimen | |||
ECX | 60 (68.18%) | 18 (72.00%) | 0.64 |
ECF | 25 (28.41%) | 7 (28.00%) | |
ECF/ECX | 3 (3.41%) | 0 (0.00%) | |
cT-stage | |||
T1/2 | 10 (11.36%) | 6 (24.00%) | 0.19 |
T3/4a | 72 (81.82%) | 17 (68.00%) | |
TX | 6 (6.80%) | 2 (8.00%) | |
cN-stage | |||
N0 | 23 (26.14%) | 5 (20.00%) | 0.73 |
N+ | 52 (59.09%) | 16 (64.00%) | |
NX | 13 (14.80%) | 4 (16.00%) | |
cM-stage | |||
M0 | 88 (100.00%) | 25 (100.00%) | N/A |
pT-stage | |||
pCR/T1/2 | 26 (29.55%) | 14 (56.00%) | 0.028 |
T3/4a | 62 (70.45%) | 11 (44.00%) | |
pN-stage | |||
N0 | 34 (38.64%) | 13 (52.00%) | 0.33 |
N+ (N1–3) | 54 (61.36%) | 12 (48.00%) | |
pM-stage | |||
M0 | 88 (100.00%) | 25 (100.00%) | N/A |
Degree of differentiation | |||
Well | 3 (3.41%) | 3 (12.00%) | 0.20 |
Moderate | 33 (37.50%) | 8 (32.00%) | |
Poor | 51 (57.95%) | 12 (48.00%) | |
Missing | 1 (1.10%) | 2 (8.00%) | |
LVI | |||
Negative | 34 (38.64%) | 9 (36.00%) | 1.00 |
Positive | 53 (60.23%) | 15 (60.00%) | |
Missing | 1 (1.10%) | 1 (4.00%) | |
CRM | |||
R0 | 43 (48.86%) | 19 (76.00%) | 0.029 |
R1 | 45 (51.14%) | 6 (24.00%) | |
Tumour regression grade | |||
TRG 1 | 2 (2.27%) | 4 (16.00%) | 0.025 |
TRG 2 | 7 (7.95%) | 0 (0.00%) | |
TRG 3 | 18 (20.45%) | 3 (12.00%) | |
TRG 4 | 46 (52.27%) | 11 (44.00%) | |
TRG 5 | 15 (17.05%) | 7 (28.00%) | |
PET response | |||
Non-responder | 35 (39.77%) | 9 (36.00%) | 0.91 |
Responder | 53 (60.23%) | 16 (64.00%) | |
Pathological response | |||
Non-responder | 79 (89.77%) | 21 (84.00%) | 0.66 |
Responder | 9 (10.23%) | 4 (16.00%) | |
Recurrence | |||
No | 38 (43.18%) | 16 (64.00%) | 0.11 |
Yes | 50 (56.82%) | 9 (36.00%) | |
